Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccines demonstrate the ability of AAHI’s unique SARS-CoV-2 self-amplifying RNA vaccine to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2. This next-generation approach to RNA vaccine technology combines self-amplifying RNA (saRNA) with a unique nanostructured lipid carrier (NLC) delivery vehicle containing an adjuvant, and will be harnessed to drive longer lasting, broadly-protective immunity against pandemic pathogens. AAHI’s RNA vaccines can easily be freeze-dried for long-term room temperature or refrigerated stability (10+ months). The SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is currently being evaluated in liquid form in a first-in-human Phase 1 / 2 clinical trial sponsored by ImmunityBio in South Africa (NCT05370040).
